GW501516 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Also called GW501516 and endurobol. |
| Chemical formula | C21H18F3NO3S2 | Molecular weight about 453.5 g/mol. |
| Appearance | White to off-white solid | Form depends on synthesis and purity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, protected from light | Common for research chemicals. |
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
== Toxicity == Though few people come in contact with mendelevium, the International Commission on Radiological Protection has set annual exposure limits for the most stable isotope. For mendelevium-258, the ingestion limit was set at 9×105 becquerels (1 Bq = 1 decay per second). Given the half-life of this isotope, this is only 2.48 ng (nanograms). The inhalation limit is at 6000 Bq or 16.5 pg (picograms).
For services to Association Football and to Gender Equality. Rajwinder Singh. Principal Project Sponsor, Prison Infrastructure Team, Ministry of Justice. For Public Service. Dr. Sabesan Sithamparanathan, FREng. Founder and President, PervasID and Enterprise Fellow, Girton College, University of Cambridge. For services to Innovation Technology. David Alexander Smith. Departmental Records Officer and Chief Librarian, Department for Levelling Up, Housing and Communities. For services to Government Knowledge and Information Management. Marie Smith. Senior Officer, National Crime Agency. For services to Law Enforcement. Michelle Southern. Founder and Director, Street Paws. For services to Homeless People and their Pets. David Martin Sprackling. Lately Lawyer, Parliamentary Counsel, Office of the Parliamentary Counsel. For Public Service. Nicholas Stace. Chair, The Conduit Holding Company. For services to Consumers and to the Environment. Marc Howard Steene. Founder and Director, Outside In Art. For services to Art. Gavin Paul Stollar. Honorary Chair, Liberal Democrat Friends of Israel. For political service to the Jewish Community. Luigi Strinati. Delivery Director, HM Courts and Tribunals Service Wales. For Public Service. Lorraine Pfavayi Sunduza. Lately Chief Nurse, East London NHS Foundation Trust. For services to Mental and Community Health. Joanna Kathryn Swash. Group Chief Executive Officer, Moneypenny. For services to the Economy. Claire Louise Swift. Director of Social Responsibility, Making for Change. For services to the Rehabilitation of Prisoners.
Additionally, CAM providers are concerned by the closure of other CAM laboratories under CLIA, and have sought to avoid detection. Some CAM providers and laboratory personnel have not had exposure to laboratory curriculum and are unaware of CLIA requirements. CLIA is largely reliant on laboratories to self-identify themselves for enrollment. Providers of CAM laboratories have opposed CLIA oversight and suggested they be regulated by their peers or by a CAM-specific division. CAM providers have stated that they should be exempt from CLIA since CAM laboratories do not participate in health insurance. Others claim that they are exempt from CLIA because the tests are performed solely for research purposes and not used in patient care and treatment decisions. Several pathologists have stated that CAM testing falls within the scope of their medical license and should not be regulated under CLIA. CLIA provisions are geared towards CLIA-certified laboratories, but not for those that have not enrolled. When a CAM laboratory is found to be operating without a CLIA certificate, they are sent a cease and desist letter to stop testing until the laboratory is CLIA certified. There are no administrative remedies available to CMS when a laboratory refuses to enroll in CLIA and refuses to cease testing. CMS cannot impose monetary or other administrative penalties on laboratories that defy the law, but can only refer cases to other Federal or State agencies.
As described above, the use of N-terminal and side chain protecting groups is essential during peptide synthesis to avoid undesirable side reactions, such as self-coupling of the activated amino acid leading to (polymerization). This would compete with the intended peptide coupling reaction, resulting in low yield or even complete failure to synthesize the desired peptide. Two principle protecting group schemes are typically used in solid phase peptide synthesis: so-called Boc/benzyl and Fmoc/tert-butyl approaches. The Boc/Bzl strategy utilizes TFA-labile N-terminal Boc protection alongside side chain protection that is removed using anhydrous hydrogen fluoride during the final cleavage step (with simultaneous cleavage of the peptide from the solid support). Fmoc/tBu SPPS uses base-labile Fmoc N-terminal protection, with side chain protection and a resin linkage that are acid-labile (final acidic cleavage is carried out via TFA treatment). Both approaches, including the advantages and disadvantages of each, are outlined in more detail below.
Afamelanotide, sold under the brand name Scenesse, is a medication used to prevent phototoxicity and to reduce pain from light exposure for people with erythropoietic protoporphyria, a rare form of genetic sun sensitivity. Afamelanotide is a melanocortin 1 receptor (MC1 receptor) agonist and a synthetic peptide and analogue of α-melanocyte stimulating hormone. It is administered as subcutaneous implant.
Sources: en.wikipedia.org
intrinsically disordered protein (IDP) A protein (or a region or domain within a protein) that lacks any distinct, fixed three-dimensional structure or organization under physiological conditions, instead changing continuously and randomly between multiple transient conformational states rather than folding into any one stable conformation, especially in the absence of specific macromolecular interaction partners. The majority of eukaryotic proteins contain domains with intrinsic structure alongside unstructured domains. Peptide sequences lacking intrinsic order are generally characterized by high proportions of charged and hydrophilic amino acids and low proportions of hydrophobic amino acids, making them inherently flexible, accessible, and modifiable, which allows the same peptide sequence to have distinct functions across a wide variety of biochemical circumstances. They are frequently enriched in binding motifs and are common targets of post-translational modifications, giving them important roles in cell signaling pathways and as hubs in protein complexes.
Kissinger, who accompanied Nixon to China, spent much time talking to the suave Chinese Premier Zhou Enlai about Vietnam, pressing him to end the supply of arms to North Vietnam. The talks went nowhere as Zhou told Kissinger that the North Vietnamese played off China against the Soviet Union, and to cut off North Vietnam would allow it to fall into the Soviet sphere of influence. As the Chinese People's Liberation Army had been badly bloodied by the Red Army in a border war in 1969, Zhou stated that to face a two-front war with Chinese forces facing North Vietnam in the south and the Soviet Union in the north was not acceptable to his government. Zhou offered Kissinger only the vague message that China supported efforts to find peace in Vietnam while refusing to make any promises, though Kissinger also noted that Zhou declined to endorse North Vietnam's demands. Despite Nixon's coming visit, in late 1971, the Chinese drastically increased their military aid to North Vietnam and continued to send a massive amount of weapons south even as Nixon and Kissinger exchanged pleasantries with Mao and Zhou in Beijing. As usual, when the Chinese increased their supply of arms to North Vietnam, the Soviet Union did likewise, as both Communist states competed with one another for influence in Hanoi by trying to be the biggest supplier of weapons. On 30 March 1972, the PAVN launched the Easter Offensive that overran several provinces in South Vietnam while pushing the ARVN to the brink of collapse. By 1 April 1972, the 3rd ARVN division was retreating south with their families.
One penicillin unit was defined as 0.5988 micrograms of the Second International Standard. There is an older unit for penicillin V that is not equivalent to the current penicillin V unit. The reason is that the US FDA incorrectly assumed that the potency of penicillin V is the same mole-for-mole as penicillin G. In fact, penicillin V is less potent than penicillin G, and the current penicillin V unit reflects that fact.
==== Public opinion polls ==== An opinion poll of Canadians conducted by Léger in August 2020 found that a majority (68%) would not take the Russian vaccine if offered a free dose, compared to 14% who said they would take it. When Americans were asked the same question, 59% would not take the Russian vaccine if offered a free dose, compared to 24% who said they would take it. In June 2021, according to a poll conducted by Ost-Ausschuss der Deutschen Wirtschaft (German Eastern Business Association), a majority (60%) of Germans would use the Russian vaccine Sputnik V if they had the opportunity to do so. With 71% approval, the values in East Germany are significantly higher, but with 58% of the respondents there is also a solid majority in West Germany. 38% of respondents, on the other hand, would not want to use Sputnik V. In July 2020, opinion polls suggested around 90% of the Russian population had doubts about the vaccine but by September this had dropped to around half the Russian population. In May 2021, the Levada Center released a poll of 1,614 respondents from 50 regions which showed that 26% of Russians were prepared to be vaccinated with Sputnik V, while 62% were not prepared to be vaccinated. Ten percent of respondents had already been vaccinated.
In 1935, at the invitation of his close British friends and colleagues, H. G. Baynes, E. A. Bennet and Hugh Crichton-Miller, Jung gave a series of lectures at the Tavistock Clinic in London, later published as part of the Collected Works. In 1938, Jung was awarded an honorary degree by the University of Oxford.At the tenth International Medical Congress for Psychotherapy held at Oxford from 29 July to 2 August 1938, Jung gave the presidential address, followed by a visit to Cheshire to stay with the Bailey family at Lawton Mere. In 1946, Jung agreed to become the first Honorary President of the newly formed Society of Analytical Psychology in London, having previously approved its training programme devised by Michael Fordham.
Sources: en.wikipedia.org
=== U.S. Department of Agriculture === In 1905, Pennington worked for the U.S. Department of Agriculture Bureau of Chemistry, which later became the U.S. Food and Drug Administration. Her director at the Bureau of Chemistry, Harvey W. Wiley, encouraged her to apply for a position as chief of the newly created Food Research Laboratory, which had been established to enforce the Pure Food and Drug Act of 1906. She was submitted to the position under the name M.E. Pennington in order to hide her gender. She accepted the position in 1907 and became the first female lab chief. One of her major accomplishments was the development of standards for the safe processing of chickens raised for human consumption. She also served as head of an investigation of refrigerated boxcar design and served on Herbert Hoover's War Food Administration during World War I.
The ribbons' conductance exceeds predictions by a factor of 10. The ribbons can function more like optical waveguides or quantum dots, allowing electrons to flow smoothly along the ribbon edges. In copper, resistance increases proportionally with length as electrons encounter impurities. Transport is dominated by two modes: one ballistic and temperature-independent, and the other thermally activated. Ballistic electrons resemble those in cylindrical carbon nanotubes. At room temperature, resistance increases abruptly at a specific length—the ballistic mode at 16 micrometers and the thermally activated mode at 160 nanometers (1% of the former length). Graphene electrons can traverse micrometer distances without scattering, even at room temperature.
=== Measurement methods === Traditional CRP measurement only detected CRP in the range of 10 to 1,000 mg/L, whereas high sensitivity CRP (hs-CRP) detects CRP in the range of 0.5 to 10 mg/L. hs-CRP can detect cardiovascular disease risk when in excess of 3 mg/L, whereas below 1 mg/L would be low risk. Traditional CRP measurement is faster and less costly than hs-CRP, and can be adequate for some applications, such as monitoring hemodialysis patients. Current immunoassay methods for CRP have similar precision to hsCRP performed by nephelometry and could probably replace hsCRP for cardiovascular risk assessment, however, in the United States this would represent off-label use, making it a laboratory-developed test under FDA regulations.
== Career == Harrington was a programmer at the video game developer Dynamix and a designer on the Windows NT operating system at Microsoft. In 1996, he founded Valve with Gabe Newell, another former Microsoft employee. Harrington sold his Microsoft shares to fund his half of the startup. His wife at the time, Monica Harrington, was Valve's marketing strategist in its early years. Harrington worked as a programmer on Valve's first game, Half-Life (1998), and funded its development with Newell. It was a critical and commercial success. Harrington said: "At Microsoft you always wonder, 'Is it me being successful or is it Microsoft?' But with Half-Life I knew Gabe and I had built that product and company from scratch." On January 15, 2000, Harrington sold his stake in Valve to Newell and left to spend time with his wife. According to Newell, Harrington did not want to risk another project after the success of Half-Life. In 2006, Harrington co-founded the photo editing service Picnik with his friend and former colleague Darrin Massena. Picnik was acquired by Google in March 2010. Harrington left Google in March 2011. In January 2012, he co-founded another company with Massena, Catnip Labs. Harrington was CTO at the Committee for Children from 2016 to 2018, and CTO of Amplion from November 2018 until March 2020.
Sources: en.wikipedia.org
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.
It activates PPARδ, a nuclear receptor that influences gene expression related to lipid and energy metabolism. Animal studies show changes in endurance and lipid levels. Human effects and risks are not well established.
No, cardarine is not a steroid. It belongs to a different chemical class, the PPARδ agonists. It is also not a selective androgen receptor modulator.
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.